Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 4/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853560 | 0.93 | GPR52 (0.46) | GPR52S1PR5S1PR4POLQNPC1 | |
| SCHEMBL1855236 | 0.90 | GPR52 (0.45) | GPR52S1PR5S1PR4PTGER1FOLH1 | |
| SCHEMBL1855238 | 0.90 | GPR52 (0.47) | GPR52S1PR5S1PR4PTGER1PPARG | |
| SCHEMBL1856606 | 0.89 | GPR52 (0.48) | GPR52S1PR5S1PR4NPC1 | |
| SCHEMBL3206759 | 0.87 | GPR52 (0.63) | GPR52 | |
| SCHEMBL1854846 | 0.86 | GPR52 (0.44) | GPR52S1PR5S1PR4PTGER1FOLH1 | |
| SCHEMBL1855969 | 0.85 | GPR52 (0.45) | GPR52S1PR5PTK2NPC1 | |
| SCHEMBL1848254 | 0.80 | GPR52 (0.47) | GPR52S1PR5S1PR4PPARGNPC1 | |
| SCHEMBL1848252 | 0.79 | GPR52 (0.44) | GPR52S1PR5S1PR4NPC1 | |
| SCHEMBL1851226 | 0.79 | GPR52 (0.47) | GPR52S1PR5S1PR4PTGER1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885S1PR5 696/4885S1PR4 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.